Sugi Predict

Sugi Predict / Targets / UNG

UNG

Uracil-DNA glycosylase · P13051 · UNG on Sugi Atlas →

4,750 patent compounds predicted against UNG, 3,248 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1506784 SCHEMBL1506784 1.00 7/20
SCHEMBL3497866 SCHEMBL3497866 0.90 5/20
SCHEMBL1423225 SCHEMBL1423225 0.57 4/20
SCHEMBL60027 SCHEMBL60027 0.58 3/20
SCHEMBL60134 SCHEMBL60134 0.58 3/20
SCHEMBL61358 SCHEMBL61358 0.58 3/20
SCHEMBL284616 SCHEMBL284616 0.58 3/20
SCHEMBL294666 SCHEMBL294666 0.58 3/20
SCHEMBL295036 SCHEMBL295036 0.58 3/20
SCHEMBL2391508 SCHEMBL2391508 0.58 3/20
SCHEMBL258169 SCHEMBL258169 0.56 3/20
SCHEMBL380602 SCHEMBL380602 0.55 3/20
SCHEMBL1423027 SCHEMBL1423027 0.54 3/20
SCHEMBL449939 SCHEMBL449939 0.52 3/20
SCHEMBL1264648 SCHEMBL1264648 0.52 3/20
SCHEMBL1266331 SCHEMBL1266331 0.52 3/20
SCHEMBL2493792 SCHEMBL2493792 0.52 3/20
SCHEMBL2687626 SCHEMBL2687626 0.52 3/20
SCHEMBL1824734 SCHEMBL1824734 0.50 3/20
SCHEMBL160938 SCHEMBL160938 0.49 3/20

Clinical trials — most relevant to UNG by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment PHASE4RECRUITING
Combination Chemotherapy in Treating Patients With Resected Colon Cancer PHASE3COMPLETED
Thiopurine EnhAnced Maintenance Therapy PHASE1/PHASE2COMPLETED
Capecitabine and Temozolomide for Neuroendocrine Cancers PHASE2COMPLETED
NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Microsatellite Stable, MGMT Silenced Metastatic Colorectal Cancer PHASE2COMPLETED
Prospective Phase II Randomized Trial of Postoperative Adjuvant Chemotherapy in Patients With High Risk Colon Cancer PHASE2UNKNOWN
A Trial of Gemcitabine, Infusional 5-Fluorouracil and Cisplatin for Advanced Pancreatic and Biliary Cancers PHASE2COMPLETED
Satraplatin and Prednisone to Treat Prostate Cancer PHASE2COMPLETED
Phase II Study of Ribose, Uridine, and Thymidine for a Complex Syndrome Involving Excessive 5'-Nucleotidase Activity PHASE2COMPLETED
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies PHASE1/PHASE2RECRUITING
Chlorambucil in Metastatic PDAC Patients Bearing a Germ Line DNA Defects Repair Mutations (SALE Trial) PHASE2UNKNOWN
S0713: Oxaliplatin, Capecitabine, Cetuximab, and RT Followed By Surgery in Pts W/Stage II or III Rectal Cancer PHASE2COMPLETED
Phase II ABT-888 With Cyclophosphamide PHASE2COMPLETED
A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma PHASE1RECRUITING
ABT-888 Plus Metronomic Cyclophosphamide to Treat Cancer PHASE1COMPLETED
Oxaliplatin Plus Capecitabine in Treating Patients With Colorectal, Appendix, or Small Bowel Cancer PHASE1COMPLETED
A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors PHASE1COMPLETED
Combination Chemotherapy in Treating Patients Who Have Advanced Solid Tumors PHASE1COMPLETED
Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Solid Tumors PHASE1COMPLETED
Expression of TET1 Gene in Acute Leukaemia nanUNKNOWN
Application of Genetic Polymorphisms of DNA Repair in The Prediction of Prostate Cancer Susceptibility and Its Clinical Outcome nanUNKNOWN
A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients nanCOMPLETED
DNA Repair Genes and Outcomes in Patients With Stage III NSCLC nanUNKNOWN
DNA Adductomics for Colorectal Cancer Investigation nanUNKNOWN
Prospective Multicenter Registry Study to Assess the Frequency of Lynch Syndrome Among Patients With Colorectal Cancer nanRECRUITING
Study of Markers of Cosmic Radiation Exposure and Effect Among Flight Crews nanCOMPLETED
Implementation and Quality Assurance of DPYD-genotyping in Patients Treated With Fluoropyrimidines. nanCOMPLETED
Thymidine Kinase 1 in Risk Assessment for Hereditary Breast /Ovarian Cancer nanUNKNOWN
Predicting Response to Capecitabine in Women With Metastatic Breast Cancer nanCOMPLETED
Comparison of Oxidants and Antioxidants in Breastmilk Under Different Anesthesia Protocols nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a UNG binder may also engage these)

ProteinNameSimilarity
P97931 — 0.996 P97931 →
O74834 — 0.987 O74834 →
P28866 — 0.986 P28866 →
Q8UCM8 — 0.986 Q8UCM8 →
Q9U221 — 0.986 Q9U221 →
Q9LIH6 — 0.985 Q9LIH6 →
Q9YGN6 — 0.985 Q9YGN6 →
P12888 — 0.985 P12888 →
P69859 — 0.984 P69859 →
Q9RWH9 — 0.982 Q9RWH9 →
O36395 — 0.982 O36395 →
F5HFA1 — 0.982 F5HFA1 →
Q9J3N2 — 0.982 Q9J3N2 →
Q9PA28 — 0.981 Q9PA28 →
P53765 — 0.981 P53765 →
P09307 — 0.981 P09307 →
A6UDC0 — 0.980 A6UDC0 →
Q01019 — 0.978 Q01019 →
Q1JHA5 — 0.978 Q1JHA5 →
A4WDE9 — 0.978 A4WDE9 →
B0U620 — 0.978 B0U620 →
P52447 — 0.978 P52447 →
P52345 — 0.977 P52345 →
Q879Z0 — 0.977 Q879Z0 →
A2RF00 — 0.977 A2RF00 →
B2IAB2 — 0.977 B2IAB2 →
Q5GUS2 — 0.977 Q5GUS2 →
P12887 — 0.977 P12887 →
Q2NY21 — 0.977 Q2NY21 →
B2SJF5 — 0.977 B2SJF5 →